I describe a gas-chromatographic procedure involving a nitrogen detector for "free" (or "unbound") phenytoin in the concentration range 0.2-4.0 mg/L in ultrafiltrates of plasma. The CV (n = 10) for the assay was 2.9% for a 0.49 mg/L concentration, 1.5% for 2.02 mg/L. The sensitivity was 0.05 mg/L. The ultrafiltration process ("Ultra-Free" filters) used to separate the free phenytoin fraction from the bound fraction was tested. The mean of and CV for free phenytoin concentrations measured in eight replicate serum filtrates were 0.68 mg/L and 15%; for eight replicate plasma filtrates the values were 0.42 mg/L and 2.9%. Thus serum is not suitable for this procedure. Storage of plasma before filtration under a wide variety of times and temperatures has an insignificant effect upon the filtration process. Some evidence was found of occasional protein "leakage" through the filters.
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The total concentration of a drug in blood consists of a "bound" (by protein) fraction and a so-called free, or unbound, fraction.
Only the free drug is pharmacologically active (1) . Consequently, the "therapeutic range" of a drug is better expressed in terms of the concentration of free drug, especially in the case of a highly (>90%) protein-bound drug. However, such measurements are difficult (e.g., by equilibrium dialysis) and so the therapeutic ranges are usually given in terms of total drug concentrations.
In several types of situations, however, the total drug concentration can be within the therapeutic range, while the free drug concentration is well above or below its more important therapeutic range. As a result, the patient is either in a toxic state or his disorder is not being controlled.
Such situations arise when the patient has an unusually high or low bloodprotein concentration, the drug-binding characteristics of the blood proteins are altered by disease (2) if either serum or plasma could be used, to assess the reproducibility of the procedure, and to determine the effect of specimen storage time and temperature on the filtration process. Phenytoin was chosen as the test drug, because it is used extensively and is highly protein-bound (4). Another problem associated with free-drug concentration measurements is that in the case of highly (90-99%) proteinbound drugs the concentration of free drug in the ultrafiltrate will be much less than the total concentration in the plasma or serum, and thus the analytical methodology may have to be 10-to 100-fold more sensitive, and increased attention must be given to interferences.
Accordingly, another purpose of this study was to develop a gas-chromatographic method involving a nitrogen-sensitive detector for measurement of phenytoin in plasma and serum ultrafiltrates.
Because the therapeutic range for total phenytoin is 5 to 20 mg/U (5) and the protein binding is 90-95% (4), the standard curve should be linear in the range 0.2 to 4.0 mg/U. 
Materials and Methods

Materials
Instrumentation
A Perkin-Elmer Model 3920B gas chromatograph with a nitrogen-phosphorus detector was modified slightly by covering all the holes on the top of the detector cover with aluminum foil, a modification that eliminated baseline noise apparently caused by room air currents. The 180 X 0.2 cm glass column was packed with 3% OV-17 on 100/120 Gas Chrom Q (Applied Science Division, Milton Roy Co., State College, PA 16801). The column (with the detector end disconnected) was conditioned by heating to 280 #{176}C with 20 mU/mm carrier-gas flow, then heating at 350 #{176}C for 4 h with no carrier-gas flow. After the column had cooled to 280 #{176}C, the carrier gas was turned on as before and the column was baked overnight at 280 #{176}C, then connected to the detector. For the phenytoin assay, the chromatographic conditions were: oven 260 #{176}C, injector and detector 250 #{176}C, helium carrier-gas flow 20 mU/mm, hydrogen flow 4.0 mU/mm, air flow 80 mL/min, potentiometer setting 450, attenuation 8 X 10.
Procedures
Filtration procedure.
Place about 1 mU of plasma or serum in the filter, attach a 3-mL plastic syringe and, after a 2-mm wait, pull the syringe plunger to the 2.9 mU mark and secure it. When the desired amount of filtrate is collected (0.3-0.5 mL in 40-60 mm), release the syringe plunger, detach the syringe from the filter, and transfer the filtrate to a test tube.
Stopper the tube and store at 4 #{176}C.
Free phenytoin
assay. To 100 sU of the filtrate or standard in a 12 X 75 mm glass tube add 50 L of 5 mol/U sulfuric acid and 1.0 mU of the free phenytoin extraction solution.
Vortex-mix for 15s, stopper, and centrifuge at 1000 X g for 60s. Carefully decant the upper layer into another 12 X 75 mm tube and evaporate in a 45 #{176}C water bath under a gentle air flow. To the residue add 50 fLL of the derivatizing reagent, vortex-mix for 5 s, and place (unstoppered) in a 45 #{176}C water bath. After 20 mm add two drops of de-ionized water and 1.0 mL of n-hexane, vortex-mix for 15s, stopper, and centrifuge for 60 s at 1000 X g. 
Results and Discussion
Derivatization Reagent
I found the popular on-column methylation procedure for gas-chromatographic analysis for phenytoin (6) to be unsuitable for low phenytoin concentrations. Therefore I optimized the pre-injection derivatization procedure of Greeley (7) for free phenytoin analysis. The butyl derivative of phenytoin was the only n-alkyl derivative (from C1 to C7 alkyl iodides) that gave a well-defined chromatographic peak and was chromatographically resolved from filtrate and reagent impurities in the concentration range studied. The optimized mixture described above was both efficient and convenient. The mixture formed no precipitate and was stable at -20 #{176}C for at least 19 days. Time after venipuncture.
C Insufficient sample for protein analysis. To examine this question, I prepared saline-based solutions of the drugs in question at concentrations expected in filtrates of plasma samples containing the highest therapeutic concentrations of these drugs. The solutions were assayed according to the free phenytoin procedure; the results (Table 1) were expressed as apparent phenytoin concentrations. Evidently, even at their highest therapeutic concentrations, chiorpromazine and disopyramide are not extracted, and interference by diazepam is below the sensitivity limit of the procedure.
Thus interference from these drugs is not expected to be a problem.
Reproducibility of Assay of Phenytoin in Ultrafiltrates
Several tubes of coagulated and anti-coagulated (heparmnized) blood were collected by venipuncture from a volunteer who was taking phenytoin.
The contents of the anti-coagulated tubes were pooled, mixed well, and centrifuged for 10 mm at 1000 X g. The resulting plasma samples were pooled, mixed well, and eight 1.0-mU replicates were filtered and the filtrates assayed for phenytoin.
The mean phenytoin concentration was 418 (SD 12) tg/U (CV 2.9%).
The coagulated tubes were allowed to stand 45 mm at room temperature, then centrifuged for 15 mm at 1000 X g. The resulting serum specimens were pooled, mixed well, and eight 1.0-mU replicates were filtered and the filtrates assayed for free phenytoin.
The mean phenytoin concentration was 675 (SD 101) big/U (CV 15.0%).
From these data it is evident that the plasma filtration process is quite reproducible-because the precision is the same as that found in the within-run and day-to-day reproducibility studies-and that the results for filtered serum are quite irreproducible.
Thus serum is not a suitable specimen for this procedure.
Specimen
Stability to Storage Blood specimens were collected as before, but the pooled plasma and serum samples were stored under various conditions of time and temperature before being filtered. Some anti-coagulated specimens were stored uncentrifuged before filtration. Each filtrate then was assayed in duplicate or triplicate for free phenytoin, and one set of filtrates also was assayed for protein content. The results are presented in Table   2 . From these data it is even more apparent that serum is not satisfactory as a specimen. The data on plasma indicate that most of the storage conditions tested will be satisfactory. The apparent small increase in free phenytoin concentrations with storage time is clinically insignificant.
The protein concentration data indicate that the filters work quite efficiently for plasma but not for serum. The fact that the serum filtrates contain a hundred-fold more protein than the plasma filtrates may explain the lack of reproducibility of the serum filtration process and the higher phenytoin concentrations in the serum filtrates. Perhaps the clotting process produces protein fragments of low molecular mass, which pass through the filter. The higher phenytoin concentrations could arise from drugs bound to these fragments, or from a higher free-drug concentration in the serum caused by the clotting process.
Finally, it appears that an occasional filter may "leak" an appreciable amount of protein, even when filtering plasma, and this may cause a falsely high value for free phenytoin concentration (see the phenytoin concentration data for the plasma filtrates having protein concentrations of 590 and 630 mg/U). Thus, if these filters are used for clinical specimens, 
Saliva Phenytoin Concentrations and Protein Binding
Plasma and serum specimens from the reproducibility and stability studies were assayed in duplicate for total phenytoin concentrations.
Saliva samples collected for 2 mm before and 2 mm after each venipuncture also were assayed in duplicate for free phenytoin.
These results were combined with the results of the filtrate assays and the protein binding percentages of phenytoin in the serum and plasma specimens were calculated. The data are presented in Table 3 . The protein-binding data are consistent with the reported values, 90-95% (4). Since saliva is considered an ultrafiltrate of blood (3), the phenytoin concentrations in saliva should be equal to those in corresponding plasma filtrates. The fact that these concentrations differ significantly in this study prompts further investigation.
